Reference | c-MET Status | PD-L1 Status | Outcome (Pembrolizumab) |
Mazieres et al. 2021 [23] | c-MET exon 14 skipping mutations (N = 36/551) | PD-L1 > 1% in 66.8% of patients | ORR: 16% mPFS: 3.4 mo. mOS: 18 mo. |
Sabari et al. 2018 [24] | c-MET exon 14 skipping mutations (N = 147) | PD-L1 > 1% in 63% of patients | ORR: 17% mPFS: 1.9 mo. mOS: 18.2 mo. |
Baba et al. 2019 [25] * | c-MET exon 14 skipping mutations (N = 1, case report) | PD-L1: 95% | refractory to IOs, responsive to chemotherapy |
Reis et al. 2018 [26] * | c-MET exon 14 skipping mutations (N = 2, case report) | PD-L1: >50% in both patients | refractory to pembrolizumab |